Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Plk1 Phosphorylation of Orc2 and Hbo1 Contributes to Gemcitabine Resistance in Pancreatic Cancer

28 Nov 2012

Abstract excerpt

Although gemcitabine is the standard chemotherapeutic drug for treatment of pancreatic cancer, almost all patients eventually develop resistance to this agent. Previous studies identified Polo-like kinase 1 (Plk1) as the mediator of gemcitabine resistance, but the molecular mechanism remains unknown. In this study, we show that Plk1 phosphorylation of Orc2 and Hbo1 mediates the resistance to gemcitabine. We show...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Microtubule and mitosis dynamics
Share to Pancreatic and Hepatic Oncology Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23188630
DOI: 10.1158/1535-7163.mct-12-0632

Provenance

PubMed metadata and Literature Corpus relationships.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Plk1 Phosphorylation of Orc2 and Hbo1 Contributes to Gemcitabine Resistance in Pancreatic CancerPMID 23188630Read ↗

PLK1 inhibition enhances gemcitabine-induced apoptosis through PLK1-dependent ERK1/2-BIM and AKT1/NOXA signals in pancreatic cancer cellsSemantic proximity Read ↗

Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancerSemantic proximity Read ↗

Deletion of ENO1 sensitizes pancreatic cancer cells to gemcitabine via MYC/RRM1-mediated glycolysisSemantic proximity Read ↗

Inhibition of Polo-like kinase 1 (PLK1) triggers cell apoptosis via ROS-caused mitochondrial dysfunction in colorectal carcinomaSemantic proximity Read ↗

Polo-like kinase1 (Plk1) knockdown enhances cisplatin chemosensitivity via up-regulation of p73α in p53 mutant human epidermoid squamous carcinoma cells.Semantic proximity Read ↗

Overcoming drug resistance in pancreatic cancer.Semantic proximity Read ↗

PDK1 Signaling Toward PLK1–MYC Activation Confers Oncogenic Transformation, Tumor-Initiating Cell Activation, and Resistance to mTOR-Targeted TherapySemantic proximity Read ↗

Polo-like kinase inhibitors: an emerging opportunity for cancer therapeuticsSemantic proximity Read ↗

Elevated PAF1-RAD52 axis confers chemoresistance to human cancersSemantic proximity Read ↗

Challenges of drug resistance in the management of pancreatic cancerSemantic proximity Read ↗

Combination of RUNX1 inhibitor and gemcitabine to mitigate chemo‐resistance in pancreatic ductal adenocarcinoma by modulating BiP/PERK/eIF2a-axis-mediated endoplasmic reticulum stressSemantic proximity Read ↗

Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.